Moderna, Inc.
MRNAModerna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Drugs in Pipeline
48
Phase 3 Programs
21
Upcoming Catalysts
7
Next Catalyst
This month
Market Overview
Stock performance and key metrics
7 upcoming, 1 past
mRNA-1189 Phase 2 Est. Readout
Primary completion for mRNA-1189 trial (NCT05164094) in Epstein-Barr Virus Infection
Source6 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How MRNA's past catalysts played out
Influsplit® Tetra
Seasonal Influenza
mRNA-1273
SARS-CoV-2
mRNA-1273.214
SARS-CoV-2
mRNA-1273.211
SARS-CoV-2
Influenza Vaccine
SARS-CoV-2
Fluarix®
Seasonal Influenza
mRNA-1083
COVID-19
Investigational mRNA-1273.815
SARS-CoV-2
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Seasonal Influenza
Fluzone HD
Respiratory Syncytial Virus
mRNA-1345
Respiratory Syncytial Virus
mRNA-1010
Seasonal Influenza
mRNA-4157
Personalized Cancer Vaccine
Melanoma
Fluarix Tetra
Seasonal Influenza
mRNA-1283
COVID-19
mRNA-1018-H5
Influenza
Intismeran autogene
Non-small Cell Lung Cancer
mRNA-1283.222
COVID-19
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
Immunocompromised Patients
mRNA-1403
Acute Gastroenteritis
mRNA-1283.815
COVID-19
mRNA-1189
Epstein-Barr Virus Infection
mRNA-1975
Lyme Disease
Influenza Vaccine 1
SARS-CoV-2
mRNA-2808
Relapsed or Refractory Multiple Myeloma
mRNA-1273.214 Vaccine
COVID-19 Pandemic
mRNA-4359
Advanced Solid Tumors
mRNA-1982
Lyme Disease
mRNA-1647
Cytomegalovirus Infection
mRNA-1030
Seasonal Influenza
mRNA-1769
Smallpox
mRNA-1608
Genital Herpes
mRNA-1018 for H5N8
Influenza
mRNA-3927
Propionic Acidemia
mRNA-1073
SARS-CoV-2
mRNA-1283.211
SARS-CoV-2
Active Comparator
Seasonal Influenza
mRNA-1468
Herpes Zoster
mRNA-1893
Zika Virus
mRNA-1083 Composition 1 Dose A Lot A
Influenza
mRNA-3705
Methylmalonic Acidemia
mRNA-3745
Glycogen Storage Disease
mRNA-1010.4
Influenza
Egg-based Quadrivalent Influenza Vaccine
Influenza
mRNA-1195
Multiple Sclerosis
mRNA-1011.1
Seasonal Influenza
mRNA-1405
Norovirus Acute Gastroenteritis
Biological: mRNA-1273
SARS-CoV-2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Influsplit® Tetra | Phase 3 | Seasonal Influenza | - | - |
mRNA-1273 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.214 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.211 | Phase 3 | SARS-CoV-2 | - | - |
Influenza Vaccine | Phase 3 | SARS-CoV-2 | - | - |
Fluarix® | Phase 3 | Seasonal Influenza | - | - |
mRNA-1083 | Phase 3 | COVID-19 | - | - |
Investigational mRNA-1273.815 | Phase 3 | SARS-CoV-2 | - | - |
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza | - | - |
Fluzone HD | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1345 | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1010 | Phase 3 | Seasonal Influenza | Fast Track | - |
mRNA-4157 Personalized Cancer Vaccine | Phase 3 | Melanoma | OrphanFast TrackBreakthrough | - |
Fluarix Tetra | Phase 3 | Seasonal Influenza | - | - |
mRNA-1283 | Phase 3 | COVID-19 | Fast Track | - |
mRNA-1018-H5 | Phase 3 | Influenza | - | - |
Intismeran autogene | Phase 3 | Non-small Cell Lung Cancer | - | - |
mRNA-1283.222 | Phase 3 | COVID-19 | - | - |
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Phase 3 | Immunocompromised Patients | - | - |
mRNA-1403 | Phase 3 | Acute Gastroenteritis | - | - |
mRNA-1283.815 | Phase 3 | COVID-19 | - | - |
mRNA-1189 | Phase 2 | Epstein-Barr Virus Infection | - | - |
mRNA-1975 | Phase 2 | Lyme Disease | - | - |
Influenza Vaccine 1 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-2808 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
mRNA-1273.214 Vaccine | Phase 2 | COVID-19 Pandemic | - | - |
mRNA-4359 | Phase 2 | Advanced Solid Tumors | - | - |
mRNA-1982 | Phase 2 | Lyme Disease | - | - |
mRNA-1647 | Phase 2 | Cytomegalovirus Infection | - | - |
mRNA-1030 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1769 | Phase 2 | Smallpox | - | - |
mRNA-1608 | Phase 2 | Genital Herpes | - | - |
mRNA-1018 for H5N8 | Phase 2 | Influenza | - | - |
mRNA-3927 | Phase 2 | Propionic Acidemia | - | - |
mRNA-1073 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1283.211 | Phase 2 | SARS-CoV-2 | - | - |
Active Comparator | Phase 2 | Seasonal Influenza | - | - |
mRNA-1468 | Phase 2 | Herpes Zoster | - | - |
mRNA-1893 | Phase 2 | Zika Virus | - | - |
mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Influenza | - | - |
mRNA-3705 | Phase 2 | Methylmalonic Acidemia | - | - |
mRNA-3745 | Phase 2 | Glycogen Storage Disease | - | - |
mRNA-1010.4 | Phase 2 | Influenza | - | - |
Egg-based Quadrivalent Influenza Vaccine | Phase 2 | Influenza | - | - |
mRNA-1195 | Phase 2 | Multiple Sclerosis | - | - |
mRNA-1011.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1405 | Phase 2 | Norovirus Acute Gastroenteritis | - | - |
Biological: mRNA-1273 | Phase 2 | SARS-CoV-2 | - | - |
Influenza
6 drugs in this indication
COVID-19
5 drugs in this indication
cancer
3 drugs in this indication
Respiratory Syncytial Virus
1 drug in this indication
Melanoma
1 drug in this indication
norovirus
1 drug in this indication
Active immunization for the prevention of lower respiratory tract disease caused by RSV
1 drug in this indication
diabetes
1 drug in this indication
Respiratory Syncytial Virus (RSV)
1 drug in this indication
flu
1 drug in this indication
flu prevention
1 drug in this indication
influenza prevention
1 drug in this indication
Ebola
1 drug in this indication
Seasonal Influenza
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Moderna, Inc.'s drug pipeline?→
CatalystAlert tracks 48 drug candidates in Moderna, Inc.'s (MRNA) pipeline across Phase 3, Phase 2. Its lead program is Influsplit® Tetra (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moderna, Inc.'s next FDA catalyst?→
Moderna, Inc.'s (MRNA) next tracked catalyst is a Phase 2 expected September 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRNA biotech catalysts?→
Add MRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moderna, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.